Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Bio-Thera Starts China Trial of mAb Biosimilar for Asthma

publication date: Oct 14, 2022

Bio-Thera Solutions of Guangzhou started a Phase I trial of its Nucala® biosimilar in patients with asthma or one of two rare blood diseases. Mepolizumab is an interleukin-5 (IL-5) antagonist mAb that is administered subcutaneously. Currently, the approved drug is indicated as an add-on maintenance therapy for severe asthma patients with an eosinophilic phenotype and adult chronic rhinosinusitis patients with nasal polyposis. After the Phase I trial, Bio-Thera plans to run a global Phase III study and request approval for all indications in China, US and EU regulators. More details....

Stock Symbol: (SHA: 688177)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital